These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 17599845)

  • 1. Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients.
    Wilms EB; Touw DJ; Heijerman HG
    J Cyst Fibros; 2008 Jan; 7(1):79-84. PubMed ID: 17599845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis.
    Wilms EB; Touw DJ; Heijerman HG
    Ther Drug Monit; 2006 Apr; 28(2):219-25. PubMed ID: 16628134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection.
    Steinkamp G; Schmitt-Grohe S; Döring G; Staab D; Pfründer D; Beck G; Schubert R; Zielen S
    Respir Med; 2008 Nov; 102(11):1643-53. PubMed ID: 18701270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daily versus weekly azithromycin in cystic fibrosis patients.
    McCormack J; Bell S; Senini S; Walmsley K; Patel K; Wainwright C; Serisier D; Harris M; Bowler S
    Eur Respir J; 2007 Sep; 30(3):487-95. PubMed ID: 17537764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis--caution with trough concentrations.
    Coulthard KP; Peckham DG; Conway SP; Smith CA; Bell J; Turnidge J
    J Cyst Fibros; 2007 Apr; 6(2):125-30. PubMed ID: 16829216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azithromycin maintenance therapy in patients with cystic fibrosis: a dose advice based on a review of pharmacokinetics, efficacy, and side effects.
    Wilms EB; Touw DJ; Heijerman HG; van der Ent CK
    Pediatr Pulmonol; 2012 Jul; 47(7):658-65. PubMed ID: 22684985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long term azithromycin therapy in cystic fibrosis patients: a study on drug levels and sputum properties.
    Baumann U; King M; App EM; Tai S; König A; Fischer JJ; Zimmermann T; Sextro W; von der Hardt H
    Can Respir J; 2004 Mar; 11(2):151-5. PubMed ID: 15045047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of azithromycin in plasma and sinus mucosal tissue following administration of extended-release or immediate-release formulations in adult patients with chronic rhinosinusitis.
    Fang AF; Palmer JN; Chiu AG; Blumer JL; Crownover PH; Campbell MD; Damle BD
    Int J Antimicrob Agents; 2009 Jul; 34(1):67-71. PubMed ID: 19307106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection.
    Moriarty TF; McElnay JC; Elborn JS; Tunney MM
    Pediatr Pulmonol; 2007 Nov; 42(11):1008-17. PubMed ID: 17902147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis.
    Massie J; Cranswick N
    J Paediatr Child Health; 2006 Oct; 42(10):601-5. PubMed ID: 16972966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis.
    Gibson RL; Retsch-Bogart GZ; Oermann C; Milla C; Pilewski J; Daines C; Ahrens R; Leon K; Cohen M; McNamara S; Callahan TL; Markus R; Burns JL
    Pediatr Pulmonol; 2006 Jul; 41(7):656-65. PubMed ID: 16703579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azithromycin increases chloride efflux from cystic fibrosis airway epithelial cells.
    Oliynyk I; Varelogianni G; Schalling M; Asplund MS; Roomans GM; Johannesson M
    Exp Lung Res; 2009 Apr; 35(3):210-21. PubMed ID: 19337904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen.
    Liu P; Allaudeen H; Chandra R; Phillips K; Jungnik A; Breen JD; Sharma A
    Antimicrob Agents Chemother; 2007 Jan; 51(1):103-9. PubMed ID: 17060516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients.
    Hansen CR; Pressler T; Hoiby N; Johansen HK
    J Cyst Fibros; 2009 Jan; 8(1):58-62. PubMed ID: 18849202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients.
    Lam W; Tjon J; Seto W; Dekker A; Wong C; Atenafu E; Bitnun A; Waters V; Yau Y; Solomon M; Ratjen F
    J Antimicrob Chemother; 2007 Jun; 59(6):1135-40. PubMed ID: 17446242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin.
    Rotschild M; Elias N; Berkowitz D; Pollak S; Shinawi M; Beck R; Bentur L
    Clin Exp Med; 2005 Jul; 5(2):80-5. PubMed ID: 16096858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg.
    Danesi R; Lupetti A; Barbara C; Ghelardi E; Chella A; Malizia T; Senesi S; Angeletti CA; Del Tacca M; Campa M
    J Antimicrob Chemother; 2003 Apr; 51(4):939-45. PubMed ID: 12654753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characterization of macrolide resistance determinants [erm(B) and mef(A)] in Streptococcus pneumoniae and viridans group streptococci (VGS) isolated from adult patients with cystic fibrosis (CF).
    Tazumi A; Maeda Y; Goldsmith CE; Coulter WA; Mason C; Millar BC; McCalmont M; Rendall J; Elborn JS; Matsuda M; Moore JE
    J Antimicrob Chemother; 2009 Sep; 64(3):501-6. PubMed ID: 19584106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial.
    Wolter J; Seeney S; Bell S; Bowler S; Masel P; McCormack J
    Thorax; 2002 Mar; 57(3):212-6. PubMed ID: 11867823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sinus fluid penetration of oral clarithromycin and azithromycin in patients with acute rhinosinusitis.
    Margaritis VK; Ismailos GS; Naxakis SS; Mastronikolis NS; Goumas PD
    Am J Rhinol; 2007; 21(5):574-8. PubMed ID: 17999793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.